Coronavirus disease-19 infection and angioedema in African Americans: A case series
Rationale: Few case series have described the simultaneous development of angioedema in patients with coronavirus 19 disease (COVID-19). Most of these reports were described in at-risk patients for developing bradykinin angioedema. Therefore, we aim to describe 5 African American patients who develo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Otolaryngology Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468548822000662 |
| _version_ | 1811220175217754112 |
|---|---|
| author | Jose Manuel Martinez Manzano Otoniel Ysea-Hill Brenda Chiang Simone A. Jarrett Kevin Bryan Lo Zurab Azmaiparashvili |
| author_facet | Jose Manuel Martinez Manzano Otoniel Ysea-Hill Brenda Chiang Simone A. Jarrett Kevin Bryan Lo Zurab Azmaiparashvili |
| author_sort | Jose Manuel Martinez Manzano |
| collection | DOAJ |
| description | Rationale: Few case series have described the simultaneous development of angioedema in patients with coronavirus 19 disease (COVID-19). Most of these reports were described in at-risk patients for developing bradykinin angioedema. Therefore, we aim to describe 5 African American patients who developed simultaneous COVID-19 and angioedema. Methods: This was a case series of hospitalized patients with simultaneous angioedema and COVID-19 infection in a single center from May 2020 to February 2022. We used descriptive statistics. The study was approved by the institutional review board. Results: Their median age was 55 years (range 28–66); all patients were African American, and 3/5 were males. All patients developed angioedema within a week of hospitalization. Two subjects had prior history of ACEI-related angioedema but were not exposed to ACEI recently, whereas 1 subject was on chronic lisinopril therapy for the last 3 years. All patients had orofacial involvement; the most common locations were lips (5/5) and tongue (3/5). None had histaminergic features of angioedema (either skin rash or peripheral eosinophilia). 4/5 subjects had respiratory symptoms and chest imaging features of COVID-19 pneumonia, whereas 3/5 subjects developed severe COVID-19 infection. Most patients were treated with standard combination of H1 and H2 blockers, and corticosteroids. A total of 2/5 subjects were intubated; one patient developed refractory tongue swelling, received tracheostomy for extubation, and died due to COVID-19 pneumonia. The median length of angioedema improvement was 44 hours (range 20–168 hours). The median length of hospital stay was 15 days (range 1–49). Conclusion: We described 5 cases of angioedema in COVID-19 patients that shared risk factors and features of bradykinin-related angioedema. |
| first_indexed | 2024-04-12T07:37:03Z |
| format | Article |
| id | doaj.art-b9e66e51b787486abc2283418f803372 |
| institution | Directory Open Access Journal |
| issn | 2468-5488 |
| language | English |
| last_indexed | 2024-04-12T07:37:03Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Otolaryngology Case Reports |
| spelling | doaj.art-b9e66e51b787486abc2283418f8033722022-12-22T03:41:55ZengElsevierOtolaryngology Case Reports2468-54882022-09-0124100457Coronavirus disease-19 infection and angioedema in African Americans: A case seriesJose Manuel Martinez Manzano0Otoniel Ysea-Hill1Brenda Chiang2Simone A. Jarrett3Kevin Bryan Lo4Zurab Azmaiparashvili5Department of Medicine, Einstein Medical Center Philadelphia, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USA; Corresponding author. Department of Internal Medicine, Einstein Medical Center Philadelphia, 5501 Old York Road, Philadelphia, PA, 19141, USA.Department of Medicine, Einstein Medical Center Philadelphia, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USADepartment of Medicine, Einstein Medical Center Philadelphia, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USADepartment of Medicine, Einstein Medical Center Philadelphia, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USADepartment of Medicine, Einstein Medical Center Philadelphia, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USADepartment of Medicine, Einstein Medical Center Philadelphia, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USARationale: Few case series have described the simultaneous development of angioedema in patients with coronavirus 19 disease (COVID-19). Most of these reports were described in at-risk patients for developing bradykinin angioedema. Therefore, we aim to describe 5 African American patients who developed simultaneous COVID-19 and angioedema. Methods: This was a case series of hospitalized patients with simultaneous angioedema and COVID-19 infection in a single center from May 2020 to February 2022. We used descriptive statistics. The study was approved by the institutional review board. Results: Their median age was 55 years (range 28–66); all patients were African American, and 3/5 were males. All patients developed angioedema within a week of hospitalization. Two subjects had prior history of ACEI-related angioedema but were not exposed to ACEI recently, whereas 1 subject was on chronic lisinopril therapy for the last 3 years. All patients had orofacial involvement; the most common locations were lips (5/5) and tongue (3/5). None had histaminergic features of angioedema (either skin rash or peripheral eosinophilia). 4/5 subjects had respiratory symptoms and chest imaging features of COVID-19 pneumonia, whereas 3/5 subjects developed severe COVID-19 infection. Most patients were treated with standard combination of H1 and H2 blockers, and corticosteroids. A total of 2/5 subjects were intubated; one patient developed refractory tongue swelling, received tracheostomy for extubation, and died due to COVID-19 pneumonia. The median length of angioedema improvement was 44 hours (range 20–168 hours). The median length of hospital stay was 15 days (range 1–49). Conclusion: We described 5 cases of angioedema in COVID-19 patients that shared risk factors and features of bradykinin-related angioedema.http://www.sciencedirect.com/science/article/pii/S2468548822000662 |
| spellingShingle | Jose Manuel Martinez Manzano Otoniel Ysea-Hill Brenda Chiang Simone A. Jarrett Kevin Bryan Lo Zurab Azmaiparashvili Coronavirus disease-19 infection and angioedema in African Americans: A case series Otolaryngology Case Reports |
| title | Coronavirus disease-19 infection and angioedema in African Americans: A case series |
| title_full | Coronavirus disease-19 infection and angioedema in African Americans: A case series |
| title_fullStr | Coronavirus disease-19 infection and angioedema in African Americans: A case series |
| title_full_unstemmed | Coronavirus disease-19 infection and angioedema in African Americans: A case series |
| title_short | Coronavirus disease-19 infection and angioedema in African Americans: A case series |
| title_sort | coronavirus disease 19 infection and angioedema in african americans a case series |
| url | http://www.sciencedirect.com/science/article/pii/S2468548822000662 |
| work_keys_str_mv | AT josemanuelmartinezmanzano coronavirusdisease19infectionandangioedemainafricanamericansacaseseries AT otonielyseahill coronavirusdisease19infectionandangioedemainafricanamericansacaseseries AT brendachiang coronavirusdisease19infectionandangioedemainafricanamericansacaseseries AT simoneajarrett coronavirusdisease19infectionandangioedemainafricanamericansacaseseries AT kevinbryanlo coronavirusdisease19infectionandangioedemainafricanamericansacaseseries AT zurabazmaiparashvili coronavirusdisease19infectionandangioedemainafricanamericansacaseseries |